Nevertheless, the compositional bias of our breast cancer cohort was a critical limitation that precluded a comprehensive evaluation of our assay’s performance for HER2 amplification status, a key biomarker for this malignancy. This evidence concerns the gene ERBB2 and breast carcinoma.